08/28/2026
Pancreatic cancer is one of the most difficult cancers to treat; however, a newly FDA-approved targeted therapy called daraxonrasib, sold under the brand name Rasonque, now offers another treatment option for certain adults with metastatic pancreatic adenocarcinoma.
Agnel Raparthi, M.D., a board-certified hematologist and oncologist at the INTEGRIS Health Cancer Institute, explains how daraxonrasib works, who may be eligible and what patients should discuss with their cancer care team.
https://bit.ly/4ixjgDR
Learn how FDA-approved daraxonrasib treats metastatic pancreatic cancer, who may qualify and what the RASolute 302 survival results showed for this promising new treatment.